Items

• Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019-02)

  B. Godman, A. Hill, S. Simoens, A. Kurdi, J. Gulbinovic, A. Margus, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Hoxha, C. Rodrigues, C. Hierlander, A. Malaj, R. Sauremann, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, G. Selke, J. Yfantopoulos, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. Valk, C. Hagen, A. Ringerud, R. Plisko, M. Wladysiuk, V. Marković Peković, N. Grubiša, T. Ponorac, I. Mardare, T. Novakovic, M. Parker, J. Fraeyman, D. Tomek, M. Obach Cortadellas, C. Zara, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, A. Heycox, Pricing of oral generic cancer medicines in 25 European countries; findings and implications, Generics and Biosimilars Initiative Journal, Vol. 8, No. 2, pp. 49 - 70, Feb, 2019